Biologics target bad bugs
- 作者Extance, Andy
- 卷第9卷
- 期第3期
- 印刷ISSN1474-1776
- 电子ISSN1474-1784
- 文件大小291.02KB
- 发表时间2010
- DOI10.1038/nrd3129
- 页码177-178
Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysisKatz, D.; Azraq, Y.; Eleyan, F.; Gill, S.; Peretz, T.; Merimsky, O. · BMC Cancer · 2016
Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer CellsDi Desidero, Teresa; Orlandi, Paola; Gentile, Daniela; Bocci, Guido · Frontiers in Oncology · 2019
<i>Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away</i> . Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapyHarris, B. H. L.; Walsh, J. L.; Neciunaite, R.; Manders, P.; Cooper, A.; De Souza, P. · Clinical and Experimental Dermatology · 2018
An Adaptive Population Enrichment Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients with Advanced Angiosarcoma (TAPPAS Trial)Mehta, C R; Liu, L; Theuer, C · Annals of Oncology · 2018
Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib RespondersNakano, Kenji; Funauchi, Yuki; Hayakawa, Keiko; Tanizawa, Taisuke; Ae, Keisuke; Matsumoto, Seiichi; Takahashi, Shunji · Journal of Clinical Medicine · 2019
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case reportJeon, So-Yeon; Lee, Na-Ri; Yim, Chang-Yeol · BMC Nephrology · 2019
Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical CancerMonk, B. J.; Mas Lopez, L.; Zarba, J. J.; Oaknin, A.; Tarpin, C.; Termrungruanglert, W.; Alber, J. A.; Ding, J.; Stutts, M. W.; Pandite, L. N. · Journal of Clinical Oncology · 2010
1667OResults of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS)Jones, R L; Ravi, V; Brohl, A S; Chawla, S P; Ganjoo, K; Italiano, A; Attia, S; Burgess, M; Thornton, K; Cranmer, L; Liu, L; Theuer, C; Maki, R · Annals of Oncology · 2019